Noninvasive biomarkers of liver function (such as PRO-C3 in NASH) that specifically target the dynamics of liver fibrosis provide a novel tool for determining patient outcome. Our collaborators use Nordic biomarkers for patient risk stratification and prognostic enrichment in clinical trials targeting high-need, high-risk patients to increase the likelihood of success. In addition, our biomarkers are direct measures of liver fibrosis dynamics currently used to determine treatment efficacy.
Diagnosis and prediction of disease progression in Alcoholic Liver Disease (ALD), especially in cirrhosis, has proven difficult. Our diagnostic and prognostic biomarkers have the potential to greatly benefit patients by helping in the early diagnosis of the disease and initiating the most appropriate treatment at the right time.
There is an urgent need for novel biomarkers that can adequately determine the risk of disease progression as well as early response to treatment. Fibrosis is a key histological feature of immune-mediated liver disease; however, the severity of liver fibrosis is primarily determined by liver biopsy. Our biomarkers are currently being used in several ongoing clinical trials to detect rapid disease progression and monitor treatment efficacy.
In viral liver disease, there is a net formation (buildup) of scar tissue in the tissues. The balance between degradation and buildup of tissue is disturbed. Protein fingerprint biomarkers can quantify tissue turnover directly in serum or plasma samples.
Please don't hesitate to contact us if you have any questions or other inquiries.